ZNF-Mediated Resistance to Imatinib Mesylate in Gastrointestinal Stromal Tumor

Lori Rink, Michael F. Ochs, Yan Zhou, Margaret von Mehren, Andrew K. Godwin

Research output: Contribution to journalArticlepeer-review

16 Scopus citations

Abstract

Although imatinib mesylate (IM) has transformed the treatment of gastrointestinal stromal tumors (GIST), many patients experience primary/secondary drug resistance. In a previous study, we identified a gene signature, consisting mainly of Kruppel-associated box (KRAB) domain containing zinc finger (ZNF) transcriptional repressors that predict short-term response to IM. To determine if these genes have functional significance, a siRNA library targeting these genes was constructed and applied to GIST cells in vitro. These screens identified seventeen "IM sensitizing genes" in GIST cells (sensitization index (SI)

Original languageEnglish (US)
Article numbere54477
JournalPLoS One
Volume8
Issue number1
DOIs
StatePublished - Jan 30 2013

ASJC Scopus subject areas

  • General Agricultural and Biological Sciences
  • General Biochemistry, Genetics and Molecular Biology
  • General Medicine

Fingerprint

Dive into the research topics of 'ZNF-Mediated Resistance to Imatinib Mesylate in Gastrointestinal Stromal Tumor'. Together they form a unique fingerprint.

Cite this